Tranexamic acid did not fix breakthrough bleeding from the contraceptive implant

The etonogestrel implant is among the most effective contraceptives available, a small rod placed under the skin of the upper arm that prevents pregnancy for years. Its biggest drawback is not failure but bleeding: many users have frequent or prolonged spotting, and it is the single most common reason they ask to have the device removed early. Clinicians have long reached for tranexamic acid, a drug that curbs bleeding elsewhere in obstetrics and gynaecology, to try to settle it. A randomised trial has now put that habit to the test, and it failed [s1].

What the trial tested

The study was a randomised, double-blind, placebo-controlled trial, the design that best guards against wishful thinking [s1]. It enrolled etonogestrel-implant users experiencing frequent bleeding, defined as two or more separate episodes, or prolonged bleeding, defined as seven or more consecutive days of bleeding or spotting in a 30-day window [s1]. Participants were assigned to tranexamic acid, 1,300 mg three times a day, or matching placebo, for five days, starting on the third consecutive day of a bleeding episode [s1]. Anyone who did not bleed within 30 days of enrolling never started the drug and was withdrawn [s1].

The main outcome was concrete and patient-centred: the total number of days free of bleeding or spotting in the 30 days after treatment started [s1]. Participants logged their bleeding daily in an electronic diary [s1]. Between January 2024 and August 2025, 65 individuals were randomised, and 54 (83%) completed the 30 days of monitoring [s1].

What it found

Tranexamic acid made no meaningful difference on any measure that mattered. The median number of days without bleeding or spotting was 19 in the tranexamic acid group and 19 in the placebo group (P=0.38) [s1]. The two groups also matched on the median number of bleeding or spotting days while on the study drug, 5 versus 5 (P=0.71), and on the number of bleeding episodes, 2 versus 2 (P=0.71) [s1]. Satisfaction with the implant as a contraceptive and acceptability of the bleeding over the study period likewise did not differ between the groups (P=0.98 and P=0.83) [s1].

The authors' conclusion is blunt: a five-day course of tranexamic acid did not improve bleeding in implant users with frequent or prolonged bleeding patterns [s1]. This is a null result, and a clean one. The trial was small, but it was properly randomised and blinded, and the outcomes it measured were the ones users care about, days of bleeding and whether they can live with the device.

Why the result is believable

Tranexamic acid works by blocking the breakdown of blood clots, which is why it helps in conditions where heavy flow comes from an otherwise structurally normal process, such as heavy menstrual periods. Implant-related bleeding is thought to arise differently, from fragile, leaky blood vessels in a womb lining thinned and destabilised by continuous progestogen, a mechanism an antifibrinolytic drug is not well placed to fix [s1]. The trial's flat result fits that biology.

It also lands in a field that has been improvising. A 2025 review paired a survey of gynaecologists with a systematic look at the literature and found the approaches to implant bleeding "diverse, sparse, and sometimes confused," with up to 19% of practitioners unsure what to offer at all [s2]. Into that uncertainty, a negative trial is genuinely useful: it removes one option that was being used on thin evidence, and narrows the search for something that works [s1][s2].

How to read it

For women weighing the implant, the practical message is reassuring in its own way. Bleeding is common and often eases over the first months on its own, and this trial does not mean the implant should be avoided. It means that if troublesome bleeding does occur, a short course of tranexamic acid is unlikely to be the answer, and a clinician may instead consider other strategies, some short-term hormonal options among them, or, after counselling, removal [s1][s2].

The limits are worth stating plainly. The trial tested one drug, one dose and one five-day schedule; a different regimen cannot be ruled out, though there is no evidence yet that one would help [s1]. And with 65 participants it was powered to detect a substantial difference, not a small one, so a marginal benefit could have been missed, but a marginal benefit is not what patients or clinicians were hoping for [s1].

The liftable summary: in a double-blind trial, tranexamic acid did nothing for breakthrough bleeding on the contraceptive implant [s1]. It is one fewer thing to try, and a prompt to find a treatment that actually works.

This article is informational and is not medical advice. Bleeding problems with a contraceptive implant should be discussed with a clinician.

Sources

• [s1] Treatment of unfavorable bleeding patterns in contraceptive implant users with tranexamic acid: randomized clinical trial. American Journal of Obstetrics and Gynecology, published online 8 January 2026; 2026;234(5):1370-1377. Funded by the Oregon Clinical and Translational Research Institute and the Gates Foundation. https://doi.org/10.1016/j.ajog.2025.12.069
• [s2] Management of abnormal bleeding in etonogestrel-releasing implant users: quo vadis. Contraception and Reproductive Medicine, 30 September 2025. https://doi.org/10.1186/s40834-025-00399-8